Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm

REFERENCES 1. Saunders MI, Rojas AM: Management of cancer of the head and neck: A cocktail with your PORT? N Engl J Med 350:1997-1999, 2004 2. Molling JW, Langius JA, Langendijk JA, et al: Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25:862-868, 2007 3. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010 4. van der Vliet HJ, Balk SP, Exley MA: Natural killer T cell-based cancer immunotherapy. Clin Cancer Res 12:5921-5923, 2006 5. Motohashi S, Okamoto Y, Yoshino I, et al: Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 140:167-176, 2011